Seqens

Seqens

X

Find Clinical Drug Pipeline Developments & Deals by Seqens

Seqens
Developments
Full Screen View

Seqens

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Product List 2023, Corporate Presentation, Products Under Development 2023, Intermediates Product List 2022, GMP Certificate 2022, CDMO Brochure, Drug Delivery Solutions

VIDEO(s)

Corporate Video, Essential Drug Substances, Motion RD, Who is SEQENS?

DIGITAL CONTENT

2 Interviews #SpeakPharma, 58 News

APIs // Active Pharmaceutical Ingredients

129 APIs, 78 USDMF, 46 CEP/COS, 25 JDMF, 32 KDMF, 108 NDC API, 88 Listed APIs

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

KEY PRODUCTS

Cantharidin, Fluralaner, Ketamine Hydrochloride, Methimazole, Olopatadine Hydrochloride, Remimazolam Besylate, Rotigotine, Sitagliptin Hydrochloride, Sitagliptin Malate, Sitagliptin Phosphate, Sparsentan, Trofinetide, Varenicline Tartrate

SERVICES

All Services, Analytical, API Manufacturing, API & Drug Product Development

KEY SERVICES

Contract API Manufacturing Services, API Custom Synthesis & Manufacturing, HPAPI Contract Manufacturing, API Spray Drying Services

EXCIPIENTS

7 Listed Products, 4 Regulatory Filings, 4 USDMF

EXCIPIENTS BY INGREDIENTS

Poly-DL-Lactic-co-Glycolic Acid, Polyethylene Glycol Excipient, Poly lactic acid, Poly caprolactone, Vitamin E TPGS

EXCIPIENTS BY APPLICATIONS

Parenteral, Surfactant & Foaming Agents

INSPECTIONS & REGISTRATIONS

29 FDA, 30 EDQM, 9 GDUFA

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Seqens

Contact Supplier

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

Contact Supplier

Digital Content

Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

Details:

The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

Lead Product(s): 20-Hydroxyecdysone

Therapeutic Area: Infections and Infectious Diseases Product Name: Sarconeos

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Biophytis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 18, 2023

Seqens Company Banner

CPhI North America

Exhibiting

envelop Contact Supplier

POST ENQUIRY